Dr. Weil is a Professor of Medicine and Professor of Molecular Microbiology at Washington University. His professional interests include clinical and molecular parasitology, tropical medicine and global health.
Dr. Weil’s research group conducts research on filarial nematode parasites that cause important tropical diseases such as elephantiasis and river blindness. This includes basic research on parasite biology and translational research to develop improved diagnostic tests and treatments. Weil serves as the PI for the DOLF project (Death to Onchocerciasis and Lymphatic Filariasis, Funded by the Bill and Melinda Gates Foundation).
Dr. Weil no longer serves as a clinical attending on the ID service. However, he leads major clinical trials and population-based field studies in Africa and Asia. He currently mentors one pediatric ID fellow and two postdoctoral fellows. He has extensive international experience and served for many years as the principal advisor to the large international electives program for medical students at Washington University.
- BA: Harvard College, Boston, MA (1971)
- Medical Degree: Harvard Medical School, Boston, MA (1975)
- Residency, Internal Medicine: Yale-New Haven Hospital, New Haven, CT (1978)
- Research Associate, Laboratory of Parasitic Diseases: NIAID, Bethesda, MD (1981)
- Fellowship, Infectious Diseases: Washington University School of Medicine, St. Louis, MO (1982)
- Internal Medicine
- Infectious Disease
- Clinical Tropical Medicine and Traveler’s Health, (ASTMH)
- Barnes-Jewish Hospital, Lifetime Achievement Award, St. Louis, MO, May 2004
- Donald Mackay Medal for achievement in tropical public health, American Society of Tropical Medicine and Hygiene, 2013.
- Washington University School of Medicine, Faculty Achievement Award, May 2016
- 2016 Anne Maurer-Cecchini Award, which recognizes outstanding epidemiological or clinical research on neglected tropical diseases, given at the Geneva Health Forum in April 2016.
- Inaugural recipient of the Drs. Gerald and Judith Medoff Professorship in Infectious diseases (2021)
- Andersen BJ, Rosa BA, Kupritz J, Meite A, Serge T, Hertz MI, Curtis K, King CK, Mitreva M, Fischer PU, Weil GJ. Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis. PLoS Negl Trop Dis 2019;13:e0007697.
- Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, Fischer PU, et al. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. PLoS Med 2019;16:e1002839.
- King CL, Weil GJ, Kazura JW. Single dose triple drug therapy completely suppresses Wuchereria bancrofti microfilaremia for 5 years. N Eng J Med 2020;14:1956-1957.